JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
Pre-market 09:17:55 am | |||
| 146.8 USD | -1.15% |
|
147.4 | +0.42% |
| Apr. 25 | Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170 | MT |
| Apr. 24 | Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset | DJ |
Presenter SpeechLee Hambright (Analysts)All right. Excellent. Well, thanks, everyone, for comi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
146.8
USD
Average target price
173.6
USD
Spread / Average Target
+18.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.33% | 354B | |
| +24.35% | 653B | |
| +25.67% | 556B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.92% | 233B | |
| +5.13% | 201B | |
| -9.98% | 193B | |
| -6.47% | 144B | |
| -12.26% | 143B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at Bernstein 38th Annual Strategic Decisions Conference, Jun-01-2022 10
